|
ES2165768B1
(es)
|
1999-07-14 |
2003-04-01 |
Almirall Prodesfarma Sa |
Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
|
|
KR100751981B1
(ko)
|
2000-06-27 |
2007-08-28 |
라보라토리오스 살바트, 에스.에이. |
아릴알킬아민으로부터 유도된 카바메이트
|
|
NZ526580A
(en)
|
2000-12-22 |
2005-04-29 |
Almirall Prodesfarma Ag |
Quinuclidine carbamate derivatives and their use as M3 antagonists
|
|
DE60121813T2
(de)
|
2000-12-28 |
2007-09-20 |
Almirall Ag |
Neue chinuclidinderivate und medizinische zusammensetzungen, die diese verbindungen enthalten
|
|
HUP0501017A3
(en)
|
2001-12-14 |
2010-06-28 |
Targacept |
Methods and compositions for treatment of central nervous system disorders
|
|
JP4505227B2
(ja)
*
|
2001-12-20 |
2010-07-21 |
キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ |
１−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用
|
|
ES2203327B1
(es)
*
|
2002-06-21 |
2005-06-16 |
Almirall Prodesfarma, S.A. |
Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
|
|
ES2204295B1
(es)
|
2002-07-02 |
2005-08-01 |
Almirall Prodesfarma, S.A. |
Nuevos derivados de quinuclidina-amida.
|
|
AU2002345266B2
(en)
*
|
2002-07-08 |
2009-07-02 |
Ranbaxy Laboratories Limited |
3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
|
|
TWI295669B
(en)
|
2002-10-30 |
2008-04-11 |
Theravance Inc |
Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
|
|
PE20040950A1
(es)
|
2003-02-14 |
2005-01-01 |
Theravance Inc |
DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
|
|
EP1618091A1
(en)
|
2003-04-09 |
2006-01-25 |
Ranbaxy Laboratories, Ltd. |
Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
|
JP2006522787A
(ja)
|
2003-04-11 |
2006-10-05 |
ランバクシー ラボラトリーズ リミテッド |
ムスカリン様受容体アンタゴニストとしてのアザビシクロ誘導体
|
|
AR044519A1
(es)
|
2003-05-02 |
2005-09-14 |
Novartis Ag |
Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
|
|
DE602004021921D1
(de)
|
2003-05-28 |
2009-08-20 |
Theravance Inc |
Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
|
|
WO2005007645A1
(en)
|
2003-07-11 |
2005-01-27 |
Theravance, Inc. |
Substituted 4-amino-1-benzylpiperidine compounds
|
|
ES2329586T3
(es)
|
2003-11-21 |
2009-11-27 |
Theravance, Inc. |
Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
|
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
|
EP1723112A1
(en)
|
2004-03-11 |
2006-11-22 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
US7501442B2
(en)
|
2004-03-11 |
2009-03-10 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
TW200538095A
(en)
|
2004-03-11 |
2005-12-01 |
Theravance Inc |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
US7265133B2
(en)
|
2004-03-11 |
2007-09-04 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
WO2005087737A1
(en)
|
2004-03-11 |
2005-09-22 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
EP1723110A1
(en)
|
2004-03-11 |
2006-11-22 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
TWI341836B
(en)
|
2004-03-11 |
2011-05-11 |
Theravance Inc |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
JP2007528413A
(ja)
|
2004-03-11 |
2007-10-11 |
セラヴァンス， インコーポレーテッド |
ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
|
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
|
ES2246170B1
(es)
*
|
2004-07-29 |
2007-04-01 |
Almirall Prodesfarma, S.A. |
Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.
|
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
|
JP2008538104A
(ja)
|
2005-03-10 |
2008-10-09 |
セラヴァンス， インコーポレーテッド |
ムスカリン受容体アンタゴニストとして有用なビフェニル化合物
|
|
US7659403B2
(en)
|
2005-03-10 |
2010-02-09 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
TW200714587A
(en)
|
2005-03-10 |
2007-04-16 |
Theravance Inc |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
JP2008537931A
(ja)
|
2005-03-10 |
2008-10-02 |
セラヴァンス， インコーポレーテッド |
ムスカリン性レセプターアンタゴニストとして有用なビフェニル化合物
|
|
WO2006099032A1
(en)
|
2005-03-10 |
2006-09-21 |
Theravance, Inc. |
Biphenyl compounds useful as muscarinic receptor antagonists
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
JP2008546695A
(ja)
|
2005-06-13 |
2008-12-25 |
セラヴァンス， インコーポレーテッド |
ムスカリン受容体アンタゴニストとして有用なビフェニル化合物
|
|
US7732607B2
(en)
|
2005-08-22 |
2010-06-08 |
Anatoly Mazurov |
Heteroaryl-substituted diazatricycloalkanes and methods of use thereof
|
|
WO2007045477A2
(en)
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Human antibodies against il-13 and therapeutic uses
|
|
WO2007110782A1
(en)
*
|
2005-12-30 |
2007-10-04 |
Ranbaxy Laboratories Limited |
Muscarinic receptor antagonists
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
GB0602778D0
(en)
|
2006-02-10 |
2006-03-22 |
Glaxo Group Ltd |
Novel compound
|
|
PT2322525E
(pt)
|
2006-04-21 |
2013-12-26 |
Novartis Ag |
Derivados de purina para utilização como agonistas do recetor de adenosina a2a
|
|
ES2298049B1
(es)
|
2006-07-21 |
2009-10-20 |
Laboratorios Almirall S.A. |
Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
|
|
EP1882691A1
(en)
*
|
2006-07-26 |
2008-01-30 |
CHIESI FARMACEUTICI S.p.A. |
Quinuclidine derivatives as M3 antagonists
|
|
WO2008037477A1
(en)
|
2006-09-29 |
2008-04-03 |
Novartis Ag |
Pyrazolopyrimidines as p13k lipid kinase inhibitors
|
|
TW200825084A
(en)
*
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
|
RS51644B
(sr)
|
2007-01-10 |
2011-10-31 |
Irm Llc. |
Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze
|
|
EP2119716A4
(en)
*
|
2007-02-09 |
2011-06-01 |
Astellas Pharma Inc |
AZA BRIDGE CYCLE COMPOUND
|
|
US20090010923A1
(en)
*
|
2007-04-24 |
2009-01-08 |
University Of Maryland, Baltimore |
Treatment of cancer with anti-muscarinic receptor agents
|
|
CN101687851B
(zh)
|
2007-05-07 |
2013-02-27 |
诺瓦提斯公司 |
有机化合物
|
|
SA08290475B1
(ar)
|
2007-08-02 |
2013-06-22 |
Targacept Inc |
(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
|
|
WO2009046025A1
(en)
|
2007-10-01 |
2009-04-09 |
Comentis, Inc. |
Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease
|
|
EP2065385A1
(en)
*
|
2007-11-28 |
2009-06-03 |
Laboratorios SALVAT, S.A. |
Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
|
|
CL2008003651A1
(es)
|
2007-12-10 |
2009-06-19 |
Novartis Ag |
Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
|
|
AU2009203693B2
(en)
|
2008-01-11 |
2012-06-07 |
Novartis Ag |
Pyrimidines as kinase inhibitors
|
|
EP2080507A1
(en)
*
|
2008-01-15 |
2009-07-22 |
CHIESI FARMACEUTICI S.p.A. |
Pharmaceutical formulations comprising an anticholinergic drug
|
|
KR20100113163A
(ko)
|
2008-02-13 |
2010-10-20 |
타가셉트 인코포레이티드 |
알파 ７ 니코틴 작용제 및 항정신병제의 조합
|
|
CA2716936C
(en)
|
2008-02-26 |
2018-06-05 |
Elevation Pharmaceuticals, Inc. |
Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
|
|
US20100055045A1
(en)
|
2008-02-26 |
2010-03-04 |
William Gerhart |
Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
|
|
EP2100598A1
(en)
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
|
EP2100599A1
(en)
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
|
US8268834B2
(en)
|
2008-03-19 |
2012-09-18 |
Novartis Ag |
Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
|
|
CA2727196A1
(en)
|
2008-06-10 |
2009-12-17 |
Novartis Ag |
Organic compounds
|
|
EP2154136A1
(en)
|
2008-08-08 |
2010-02-17 |
CHIESI FARMACEUTICI S.p.A. |
Quinuclidine carbonate derivatives and medicinal compositions thereof
|
|
WO2010045633A2
(en)
*
|
2008-10-17 |
2010-04-22 |
National Jewish Health |
Measurement and analysis of leukotrienes
|
|
EP2206712A1
(en)
*
|
2008-12-23 |
2010-07-14 |
CHIESI FARMACEUTICI S.p.A. |
"Alkaloid aminoester derivatives and medicinal composition thereof"
|
|
TW201031664A
(en)
|
2009-01-26 |
2010-09-01 |
Targacept Inc |
Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
|
|
PL2391366T3
(pl)
|
2009-01-29 |
2013-04-30 |
Novartis Ag |
Podstawione benzimidazole do leczenia gwiaździaków
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
EA201200260A1
(ru)
|
2009-08-12 |
2012-09-28 |
Новартис Аг |
Гетероциклические гидразоны и их применение для лечения рака и воспаления
|
|
NZ598220A
(en)
|
2009-08-17 |
2014-02-28 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
|
CA2771432A1
(en)
|
2009-08-20 |
2011-02-24 |
Novartis Ag |
Heterocyclic oxime compounds
|
|
US20110098311A1
(en)
|
2009-10-22 |
2011-04-28 |
Vertex Pharmaceuticals Incorported |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
BR112012032332A2
(pt)
|
2010-06-22 |
2016-11-08 |
Chiesi Farma Spa |
composto, uso de um composto, composição farmacêutica, combinação de um composto e dispositivo
|
|
JP2013529606A
(ja)
|
2010-06-22 |
2013-07-22 |
シエシー ファルマセウティチィ ソシエタ ペル アチオニ |
抗ムスカリン薬含有乾燥粉末配合物
|
|
EP2585457B1
(en)
*
|
2010-06-22 |
2015-07-22 |
Chiesi Farmaceutici S.p.A. |
Alkaloid aminoester derivatives and medicinal composition thereof
|
|
BR112012031967A2
(pt)
|
2010-06-22 |
2019-09-24 |
Chiesi Farm Spa |
composto, uso de um composto, combinação de um composto e composição farmacêutica
|
|
UY33597A
(es)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
Compuestos y composiciones como inhibidores de la trk
|
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
|
WO2012069275A1
(en)
|
2010-11-26 |
2012-05-31 |
Chiesi Farmaceutici S.P.A. |
Glycine derivatives and their use as muscarinic receptor antagonists
|
|
KR101928505B1
(ko)
*
|
2011-01-28 |
2018-12-12 |
에스케이바이오팜 주식회사 |
피리돈 유도체 및 이를 포함하는 약학적 조성물
|
|
EP2673277A1
(en)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
|
US20120220557A1
(en)
|
2011-02-17 |
2012-08-30 |
Chiesi Farmaceutici S.P.A. |
Liquid propellant-free formulation comprising an antimuscarinic drug
|
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
MA34969B1
(fr)
|
2011-02-25 |
2014-03-01 |
Irm Llc |
Composes et compositions en tant qu inibiteurs de trk
|
|
KR101987736B1
(ko)
*
|
2011-03-18 |
2019-06-11 |
젠자임 코포레이션 |
글루코실세라마이드 합성효소 억제제
|
|
EP2510928A1
(en)
|
2011-04-15 |
2012-10-17 |
Almirall, S.A. |
Aclidinium for use in improving the quality of sleep in respiratory patients
|
|
CA2834467A1
(en)
|
2011-04-29 |
2012-11-01 |
Chiesi Farmaceutici S.P.A. |
Alkaloid ester and carbamate derivatives and medicinal compositions thereof
|
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
|
CA2848809A1
(en)
|
2011-09-15 |
2013-03-21 |
Novartis Ag |
6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
|
|
WO2013038386A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Heterocyclic compounds for the treatment of cystic fibrosis
|
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
ES2882807T3
(es)
|
2011-09-16 |
2021-12-02 |
Novartis Ag |
Heterociclil carboxamidas N-sustituidas
|
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
JP6130391B2
(ja)
|
2011-11-23 |
2017-05-17 |
インテリカイン， エルエルシー |
Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
|
|
BR112014013179A2
(pt)
|
2011-12-30 |
2017-06-13 |
Chiesi Farm Spa |
compostos, combinação de um composto, composição farmacêutica e usos de um composto
|
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
|
AU2013243097A1
(en)
|
2012-04-03 |
2014-10-09 |
Novartis Ag |
Combination products with tyrosine kinase inhibitors and their use
|
|
MA37975B2
(fr)
|
2012-09-11 |
2021-03-31 |
Genzyme Corp |
Inhibiteurs de synthase de glucosylcéramide
|
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
|
EP2968340A4
(en)
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
COMBINING KINASE INHIBITORS AND USES THEREOF
|
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
|
|
US9862711B2
(en)
|
2014-04-24 |
2018-01-09 |
Novartis Ag |
Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
BR112016024484A2
(pt)
|
2014-04-24 |
2017-08-15 |
Novartis Ag |
derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
|
|
CA2945212A1
(en)
|
2014-04-24 |
2015-10-29 |
Novartis Ag |
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
JP2017524736A
(ja)
|
2014-07-11 |
2017-08-31 |
アルファーマゲン，エルエルシー |
アルファ７−ニコチン性アセチルコリン受容体活性を調節するためのキヌクリジン化合物
|
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
|
CA2954862A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Combination therapy
|
|
US9724340B2
(en)
|
2015-07-31 |
2017-08-08 |
Attenua, Inc. |
Antitussive compositions and methods
|
|
CN114040762A
(zh)
|
2019-02-04 |
2022-02-11 |
建新公司 |
使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
|
|
AU2020290094B2
(en)
|
2019-06-10 |
2024-01-18 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
|
|
AU2020338971B2
(en)
|
2019-08-28 |
2023-11-23 |
Novartis Ag |
Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
|
|
TW202140550A
(zh)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
|
|
JP2023512366A
(ja)
|
2020-02-03 |
2023-03-27 |
ジェンザイム・コーポレーション |
リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法
|
|
AU2021311131B2
(en)
|
2020-07-24 |
2026-02-19 |
Genzyme Corporation |
Pharmaceutical compositions comprising venglustat
|